ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
US Tech 100
18,078.00
-0.21%
Dow Jones
39,869.38
-0.10%
Brent Oil
83.175
-0.04%
Bitcoin
65,469.15
0.35%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Dare Bioscience Inc (DARE) Quote

Dare Bioscience Inc

Dare Bioscience Inc (DARE)

NASDAQ
0.4348
0.0748
(20.78%)
Closed May 16 4:00PM
Delayed by 15 minutes
0.4399
0.0051
(1.17%)
After Hours: 7:54PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.4399
Bid
0.4201
Ask
0.44
Volume
925,020
0.370001 Day's Range 0.4499
0.27 52 Week Range 1.06
Market Cap
42.382M
Previous Close
0.36
Open
0.40
Last Trade
3000
@
0.4399
(formt)
Last Trade Time
Financial Volume
$ 373,213
VWAP
0.403465
Average Volume (3m)
726,412
Shares Outstanding
98,562,344
Dividend Yield
-
PE Ratio
-1.41
Earnings Per Share (EPS)
-0.31
Revenue
2.81M
Net Profit
-30.16M

About Dare Bioscience Inc

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve... Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.darebioscience.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Dare Bioscience Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DARE. The last closing price for Dare Bioscience was $0.36. Over the last year, Dare Bioscience shares have traded in a share price range of $ 0.27 to $ 1.06.

Dare Bioscience currently has 98,562,344 shares outstanding. The market capitalization of Dare Bioscience is $42.38 million. Dare Bioscience has a price to earnings ratio (PE ratio) of -1.41.

DARE Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 14 2024
Edgar (US Regulatory)

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across...

May 14 2024
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

May 13 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

May 10 2024
Edgar (US Regulatory)

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at...

May 07 2024
GlobeNewswire Inc.

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it was selected as a spoke for the Investor Catalyst Hub...

May 02 2024
GlobeNewswire Inc.

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to...

April 30 2024
GlobeNewswire Inc.

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering...

April 23 2024
GlobeNewswire Inc.

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has...

April 11 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.129941.90322580650.310.44990.3016286140.34585682CS
40.131342.54698639010.30860.44990.2811042480.31271751CS
120.074920.52054794520.3650.58990.287264120.38093702CS
260.099929.38235294120.340.58990.276367650.35712962CS
52-0.5701-56.44554455451.011.060.274489550.45991833CS
156-0.8901-66.92481203011.332.510.2718377311.61927372CS
260-0.4539-50.78317296930.89383.850.2714928081.64556207CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CRKNCrown Electrokinetics Corporation
$ 0.2321
(402.38%)
3.12B
LSDILucy Scientific Discovery Inc
$ 1.5697
(207.78%)
69.27M
GWAVGreenwave Technology Solutions Inc
$ 0.149
(149.16%)
1.93B
TOIIWOncology Institute Inc
$ 0.0998
(134.82%)
6.38k
FFIEFaraday Future Intelligent Electric Inc
$ 1.6401
(132.64%)
1.14B
LGHLWLion Group Holding Ltd
$ 0.0041
(-28.07%)
40
SYTASiyata Mobile Inc
$ 2.51
(-27.87%)
622.62k
REKRRekor Systems Inc
$ 1.3811
(-24.12%)
5.92M
EYENEyenovia Inc
$ 0.8156
(-23.06%)
1.65M
RELIReliance Global Group Inc
$ 0.29
(-21.60%)
2.97M
CRKNCrown Electrokinetics Corporation
$ 0.2321
(402.38%)
3.12B
GWAVGreenwave Technology Solutions Inc
$ 0.149
(149.16%)
1.93B
FFIEFaraday Future Intelligent Electric Inc
$ 1.6401
(132.64%)
1.14B
PEGYPineapple Energy Inc
$ 0.1467
(68.81%)
472.42M
SINTSiNtx Technologies Inc
$ 0.139999
(9.72%)
381.51M

DARE Discussion

View Posts
powerbattles powerbattles 2 days ago
$DARE took the starter! Secure $22 million in the non-dilutive & phase 2 and phase 3 coming $$$
👍️0
harry crumb harry crumb 2 weeks ago
Wouldn’t touch this turd with monopoly money until after the r/s, an after the shorting!
👍️0
Awl416 Awl416 2 weeks ago
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
👍️0
willlbone willlbone 4 weeks ago
Vote on R/S.
👍️0
glenn1919 glenn1919 3 months ago
DARE.................................................https://stockcharts.com/h-sc/ui?s=DARE&p=W&b=5&g=0&id=p86431144783
👍️0
starkd748 starkd748 5 months ago
It's dead lol
👍️0
Monksdream Monksdream 5 months ago
DARE new 52 week low
👍️0
Monksdream Monksdream 8 months ago
DARE new 52 week low
👍️0
Monksdream Monksdream 8 months ago
DARE new 52 week low
👍️0
Monksdream Monksdream 9 months ago
DARE newb52 week low
👍️0
harry crumb harry crumb 1 year ago
Might be a runner in due time
👍️0
nonsequetor nonsequetor 1 year ago
The DARE train has not even left the station... gathering up steam...
👍️0
harry crumb harry crumb 1 year ago
1.00 average, 100k
👍️0
nonsequetor nonsequetor 1 year ago
I hope everyone loaded up Monday...
👍️0
nonsequetor nonsequetor 1 year ago
Monday, Jan 23, is the day...
👍️0
harry crumb harry crumb 1 year ago
Yep agree
👍️0
nonsequetor nonsequetor 1 year ago
If Ovaprene is approved by the FDA, it could be the first monthly non-hormonal contraceptive product for women and a first-in-category option for women seeking a hormone-free, self-administered and monthly birth control method.

https://www.biospace.com/article/releases/dare-bioscience-announces-ide-approval-for-a-single-arm-open-label-pivotal-contraceptive-efficacy-study-of-ovaprene-an-investigational-hormone-free-monthly-intravaginal-contraceptive/
👍️0
nonsequetor nonsequetor 1 year ago
DARE starts revenue soon with its first approved drug, Xaciato and its licensing partner OGN. Q1 or Q2. Milestone payments and double digit royalties.

Additionally, they have up to three products entering Ph3 trials this year: Ovaprene, Sildenafil and HRT-1. Ovaprene for sure is entering Ph3 this summer with NIH and licensing partner $BAYRY.

By 2024, they could have FDA-approved products and $4-$5B market share and exclusivity.
👍️0
nonsequetor nonsequetor 1 year ago
DARE Since Post:
$0.3266
(38.27%)
Then:$0.8534
Now:$1.18

Nice chunk of change so far...
👍️0
harry crumb harry crumb 1 year ago
Mayb, mayb not
👍️0
nonsequetor nonsequetor 1 year ago
Since my call
Jan 03, 2023 9:29 AM

$DARE It has begun...

DARE Since Post:
$0.2566
(30.07%)
Then:$0.8534
Now:$1.11

UM...AH... looks like a winner already...
and it has not even started!

BUT...

I really don't care what negativity others post. I have done my DD, bought low, and will ride the wave to prosperity.

DARE is the real thing, with one of a kind, first in class products, that will turn many heads and make some (who do their own DD) wealthy.

Good fortune to all (except shorts, who bet wrong on this leg up).
👍️0
harry crumb harry crumb 1 year ago
Could be but highly unlikely this becomes a winner
👍️0
nonsequetor nonsequetor 1 year ago
Just a little bit of DD will prove you wrong.
👍️0
harry crumb harry crumb 1 year ago
Dont count on it, this team is not an has not proven anything yet. Could use new management for a change, the stock does note promote a very good company
👍️0
nonsequetor nonsequetor 1 year ago
Hop aboard, this is just the beginning!
👍️0
nonsequetor nonsequetor 1 year ago
DARE up over 30% already this year.
👍️0
nonsequetor nonsequetor 1 year ago
Up 20% in 2 days
👍️0
nonsequetor nonsequetor 1 year ago
UP 10% since yesterday morning.
👍️0
harry crumb harry crumb 1 year ago
This pos needs to be shutdown, what a scam
👍️0
harry crumb harry crumb 1 year ago
Some more news on dare
👍️0
nonsequetor nonsequetor 2 years ago
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

https://finance.yahoo.com/news/dar-bioscience-announces-subject-screening-120000980.html
👍️0
harry crumb harry crumb 2 years ago
Some news an this turd is stagnant, very boring company here
👍️0
harry crumb harry crumb 2 years ago
Looks like this pos is going to its 3 yr low of .75 area. What junk!
👍️0
nonsequetor nonsequetor 2 years ago
Q4 will be interesting
👍️0
nonsequetor nonsequetor 2 years ago
WOW!! Nice EOD catapult!!
👍️0
nonsequetor nonsequetor 2 years ago
Another week... another wait...

ZZZZZZZZZZZZZZZZZZZZZZ
👍️0
MattSav MattSav 2 years ago
Good looking week... Hope everyone is enjoying this move upwards... I know we are waiting on 4th quarter for real numbers but wondering if the sentiment here is good enough to through another 10k on shares lol
👍️0
nonsequetor nonsequetor 2 years ago
YES!
👍️0
MattSav MattSav 2 years ago
So should we be excited that they are doing Financials on a Tuesday?
👍️0
MattSav MattSav 2 years ago
So is the corporate presentation today or what I can't open the damn thing
👍️0
nonsequetor nonsequetor 2 years ago
https://www.sec.gov/Archives/edgar/data/0001401914/000149315222019342/ex3-1.htm
👍️0
MattSav MattSav 2 years ago
Anyone find out how the vote went?
👍️0
kruy kruy 2 years ago
You do realize that all the upfront payments and tiered royalties have to be split with the labs that actually invented and produce these products. DARE is only the middleman. These details are all spelled out in the last SEC annual filing.
The best thing that could happen for us shareholders is that some big company that needs a pipeline will buy out this company and its entire complicated business model. Give me $5 a share and I'm happy. Reality wise, I think we could only get $3-$4 because they would need to come to agreements with all the labs that actually engineered all of the products. Either way, I'd be happy with any buyout because the business model as is could take a long time for DARE to break even or show a profit after splitting royalties with all parties involved.
👍️0
nonsequetor nonsequetor 2 years ago
$$$$ Coming in from the Gates!
https://ih.advfn.com/stock-market/NASDAQ/dare-bioscience-DARE/stock-news/88547783/current-report-filing-8-k
👍️0
nonsequetor nonsequetor 2 years ago
This DARE stock will drive a sane man crazy!
👍️0
harry crumb harry crumb 2 years ago
Employee stock incentive plan goes into effect with dare Bod approval. Always good news to have a employee purchase plan for company stock
👍️0
MattSav MattSav 2 years ago
So im new to this stock... What are the opinions of the stock not getting its approval to increase shares?
👍️0
nonsequetor nonsequetor 2 years ago
Just a few more days...
👍️0
nonsequetor nonsequetor 2 years ago
CLINICAL TRIALS RESULTS JUST POSTED
https://www.clinicaltrials.gov/ct2/show/results/NCT03598088?view=results
👍️0
nonsequetor nonsequetor 2 years ago
👍️0

Your Recent History

NASDAQ
DARE
Dare Bioscience
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved